Unresectable Gallbladder Carcinoma Recruiting Phase 1 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0046852 (Unresectable Gallbladder Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03257761Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerTreatment